Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 20/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947403 | 1.00 | PDE9A (0.53) | PDE9APDE1C | |
| SCHEMBL30947393 | 0.91 | PDE9A (0.59) | PDE9APDE1C | |
| SCHEMBL6691131 | 0.91 | PDE9A (0.59) | PDE9APDE1C | |
| SCHEMBL30947418 | 0.89 | PDE9A (0.54) | PDE9APDE1C | |
| SCHEMBL6686742 | 0.89 | PDE9A (0.54) | PDE9APDE1C | |
| SCHEMBL6692125 | 0.88 | PDE9A (0.57) | PDE9APDE1C | |
| SCHEMBL30947401 | 0.88 | PDE9A (0.57) | PDE9APDE1C | |
| SCHEMBL6691801 | 0.88 | PDE9A (0.58) | PDE9APDE1C | |
| SCHEMBL30947389 | 0.88 | PDE9A (0.58) | PDE9APDE1C | |
| SCHEMBL7882620 | 0.85 | PDE9A (0.49) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | claimed |
| US-20210386743-A1 | USE OF PDE9 INHIBITORS FOR TREATMENT | THE JOHNS HOPKINS UNIVERSTY | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | PDE9A 1/4885PDE1C 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.